ArticleExperimental & molecular medicine2018

A small molecule approach to degrade RAS with EGFR repression is a potential therapy for KRAS mutation-driven colorectal cancer resistance to cetuximab.

Sang-Kyu Lee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.